Schizophrenia Care: Experts argue negative and cognitive symptoms are often missed in routine visits, pushing for measurement-based care and better caregiver tracking to define what “stable” really means. ADHD Diagnosis: New coverage highlights adult ADHD underdiagnosis—especially when anxiety or depression comes first—and why earlier, accurate diagnosis can improve long-term outcomes. Psychiatry Treatment Access: Clinicians urge moving to interventional options sooner in treatment-resistant depression, weighing TMS and esketamine against practical barriers like contraindications and insurance timing. Suicide Prevention: Reviews focus on evidence-based pharmacologic approaches and emerging endocrine biomarkers to better predict suicide risk in schizophrenia. Substance Use Disorder Tech: The FDA granted Breakthrough Device Designation to NET Recovery’s device for stimulant use disorder, aiming to reduce psychostimulant use without drugs. Diabetes Tech: DreaMed won FDA 510(k) clearance for CGM-driven insulin automation for people using both basal and mealtime injections. Pharma Deals & Policy: Merck licensed SciBrunch’s preclinical KRAS G12D inhibitor in a deal up to $2.13B, while a Kerala court signaled the government can intervene on exorbitantly priced patented drugs. Healthcare Business: Coverage examines how private equity hospital ownership is reshaping care delivery and costs.